{"id":"https://openalex.org/W3091987693","doi":"https://doi.org/10.1158/1078-0432.ccr-20-1690","title":"Phase I Study of the Efficacy and Safety of Ramucirumab in Combination with Osimertinib in Advanced T790M-positive EGFR -mutant Non\u2013small Cell Lung Cancer","display_name":"Phase I Study of the Efficacy and Safety of Ramucirumab in Combination with Osimertinib in Advanced T790M-positive EGFR -mutant Non\u2013small Cell Lung Cancer","publication_year":2020,"publication_date":"2020-10-12","ids":{"openalex":"https://openalex.org/W3091987693","doi":"https://doi.org/10.1158/1078-0432.ccr-20-1690","mag":"3091987693","pmid":"https://pubmed.ncbi.nlm.nih.gov/33046516","pmcid":"https://www.ncbi.nlm.nih.gov/pmc/articles/8793125"},"language":"en","primary_location":{"id":"doi:10.1158/1078-0432.ccr-20-1690","doi":"https://doi.org/10.1158/1078-0432.ccr-20-1690","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1078-0432.ccr-20-1690","pdf_url":null,"source":{"id":"https://openalex.org/S183149254","display_name":"Clinical Cancer Research","issn_l":"1078-0432","issn":["1078-0432","1557-3265"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical Cancer Research","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"green","oa_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/8793125","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5014837967","display_name":"Helena Alexandra Yu","orcid":"https://orcid.org/0000-0002-0377-9510","observed_orcids":["https://orcid.org/0000-0002-0377-9510"]},"institutions":[{"id":"https://openalex.org/I1334819555","display_name":"Memorial Sloan Kettering Cancer Center","ror":"https://ror.org/02yrq0923","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1334819555"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Helena A. Yu","raw_affiliation_strings":["1Department of Medicine, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, New York"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Department of Medicine, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, New York","institution_ids":["https://openalex.org/I1334819555"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5052765751","display_name":"Luis G Paz-Ares","orcid":"https://orcid.org/0000-0002-1947-3364","observed_orcids":["https://orcid.org/0000-0002-1947-3364"]},"institutions":[{"id":"https://openalex.org/I4210101691","display_name":"Hospital Universitario 12 De Octubre","ror":"https://ror.org/00qyh5r35","country_code":"ES","type":"healthcare","lineage":["https://openalex.org/I4210101691","https://openalex.org/I4210139293"]}],"countries":["ES"],"is_corresponding":false,"raw_author_name":"Luis G. Paz-Ares","raw_affiliation_strings":["2Medical Oncology Department, University Hospital 12 de Octubre, Madrid, Spain"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2Medical Oncology Department, University Hospital 12 de Octubre, Madrid, Spain","institution_ids":["https://openalex.org/I4210101691"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5055074037","display_name":"James Chih\u2010Hsin Yang","orcid":"https://orcid.org/0000-0002-5586-5138","observed_orcids":["https://orcid.org/0000-0002-5586-5138"]},"institutions":[{"id":"https://openalex.org/I4210131804","display_name":"National Taiwan University Hospital","ror":"https://ror.org/03nteze27","country_code":"TW","type":"healthcare","lineage":["https://openalex.org/I4210131804"]}],"countries":["TW"],"is_corresponding":false,"raw_author_name":"James Chih-Hsin Yang","raw_affiliation_strings":["3Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"3Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan","institution_ids":["https://openalex.org/I4210131804"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5005962138","display_name":"Ki Hyeong Lee","orcid":"https://orcid.org/0000-0002-7830-5950","observed_orcids":["https://orcid.org/0000-0002-7830-5950"]},"institutions":[{"id":"https://openalex.org/I163753206","display_name":"Chungbuk National University","ror":"https://ror.org/02wnxgj78","country_code":"KR","type":"education","lineage":["https://openalex.org/I163753206"]},{"id":"https://openalex.org/I4210161026","display_name":"Chungbuk National University Hospital","ror":"https://ror.org/05529q263","country_code":"KR","type":"healthcare","lineage":["https://openalex.org/I163753206","https://openalex.org/I4210161026"]}],"countries":["KR"],"is_corresponding":false,"raw_author_name":"Ki Hyeong Lee","raw_affiliation_strings":["4Division of Hematology and Oncology, Chungbuk National University Hospital, Chungbuk National University College of Medicine, Cheongju, Republic of Korea"],"raw_orcid":"https://orcid.org/0000-0002-7830-5950","affiliations":[{"raw_affiliation_string":"4Division of Hematology and Oncology, Chungbuk National University Hospital, Chungbuk National University College of Medicine, Cheongju, Republic of Korea","institution_ids":["https://openalex.org/I163753206","https://openalex.org/I4210161026"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5050766137","display_name":"Pilar Garrido","orcid":"https://orcid.org/0000-0002-5899-6125","observed_orcids":["https://orcid.org/0000-0002-5899-6125"]},"institutions":[{"id":"https://openalex.org/I4210161852","display_name":"Hospital Universitario Ram\u00f3n y Cajal","ror":"https://ror.org/050eq1942","country_code":"ES","type":"healthcare","lineage":["https://openalex.org/I4210139293","https://openalex.org/I4210161852"]}],"countries":["ES"],"is_corresponding":false,"raw_author_name":"Pilar Garrido","raw_affiliation_strings":["5Medical Oncology Department, Hospital Ram\u00f3n y Cajal, Madrid, Spain"],"raw_orcid":"https://orcid.org/0000-0002-5899-6125","affiliations":[{"raw_affiliation_string":"5Medical Oncology Department, Hospital Ram\u00f3n y Cajal, Madrid, Spain","institution_ids":["https://openalex.org/I4210161852"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5030107272","display_name":"Keunchil Park","orcid":"https://orcid.org/0000-0002-4846-7449","observed_orcids":["https://orcid.org/0000-0002-4846-7449"]},"institutions":[{"id":"https://openalex.org/I2802194831","display_name":"Samsung Medical Center","ror":"https://ror.org/05a15z872","country_code":"KR","type":"healthcare","lineage":["https://openalex.org/I2250650973","https://openalex.org/I2802194831"]},{"id":"https://openalex.org/I848706","display_name":"Sungkyunkwan University","ror":"https://ror.org/04q78tk20","country_code":"KR","type":"education","lineage":["https://openalex.org/I848706"]}],"countries":["KR"],"is_corresponding":false,"raw_author_name":"Keunchil Park","raw_affiliation_strings":["6Department of Medicine, Division of Hematology-Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea"],"raw_orcid":"https://orcid.org/0000-0002-4846-7449","affiliations":[{"raw_affiliation_string":"6Department of Medicine, Division of Hematology-Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea","institution_ids":["https://openalex.org/I2802194831","https://openalex.org/I848706"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5005188570","display_name":"Joo-Hang Kim","orcid":"https://orcid.org/0000-0003-0408-8997","observed_orcids":["https://orcid.org/0000-0003-0408-8997"]},"institutions":[{"id":"https://openalex.org/I4210134376","display_name":"CHA University Bundang Medical Center","ror":"https://ror.org/04nbqb988","country_code":"KR","type":"healthcare","lineage":["https://openalex.org/I4210134376","https://openalex.org/I4210148737","https://openalex.org/I4405258985"]},{"id":"https://openalex.org/I4210148737","display_name":"CHA University","ror":"https://ror.org/04yka3j04","country_code":"KR","type":"education","lineage":["https://openalex.org/I4210148737","https://openalex.org/I4405258985"]}],"countries":["KR"],"is_corresponding":false,"raw_author_name":"Joo-Hang Kim","raw_affiliation_strings":["7Division of Medical Oncology, Department of Internal Medicine, CHA Bundang Medical Center, Gyeonggi, Republic of Korea"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"7Division of Medical Oncology, Department of Internal Medicine, CHA Bundang Medical Center, Gyeonggi, Republic of Korea","institution_ids":["https://openalex.org/I4210134376","https://openalex.org/I4210148737"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5005962138","display_name":"Ki Hyeong Lee","orcid":"https://orcid.org/0000-0002-7830-5950","observed_orcids":["https://orcid.org/0000-0002-7830-5950"]},"institutions":[{"id":"https://openalex.org/I2801680663","display_name":"Asan Medical Center","ror":"https://ror.org/03s5q0090","country_code":"KR","type":"healthcare","lineage":["https://openalex.org/I2801680663","https://openalex.org/I4210167194"]},{"id":"https://openalex.org/I40542001","display_name":"University of Ulsan","ror":"https://ror.org/02c2f8975","country_code":"KR","type":"education","lineage":["https://openalex.org/I40542001"]}],"countries":["KR"],"is_corresponding":false,"raw_author_name":"Dae Ho Lee","raw_affiliation_strings":["8Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine Seoul, Seoul, Republic of Korea"],"raw_orcid":"https://orcid.org/0000-0002-7830-5950","affiliations":[{"raw_affiliation_string":"8Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine Seoul, Seoul, Republic of Korea","institution_ids":["https://openalex.org/I2801680663","https://openalex.org/I40542001"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5112368424","display_name":"Huzhang Mao","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I168537998","display_name":"Eli Lilly (United States)","ror":"https://ror.org/01qat3289","country_code":"US","type":"company","lineage":["https://openalex.org/I168537998"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Huzhang Mao","raw_affiliation_strings":["9Eli Lilly and Company, Indianapolis, Indiana"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"9Eli Lilly and Company, Indianapolis, Indiana","institution_ids":["https://openalex.org/I168537998"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5021147423","display_name":"Sameera R. Wijayawardana","orcid":"https://orcid.org/0000-0002-5187-167X","observed_orcids":["https://orcid.org/0000-0002-5187-167X"]},"institutions":[{"id":"https://openalex.org/I168537998","display_name":"Eli Lilly (United States)","ror":"https://ror.org/01qat3289","country_code":"US","type":"company","lineage":["https://openalex.org/I168537998"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Sameera R. Wijayawardana","raw_affiliation_strings":["9Eli Lilly and Company, Indianapolis, Indiana"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"9Eli Lilly and Company, Indianapolis, Indiana","institution_ids":["https://openalex.org/I168537998"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5101483571","display_name":"Ling Gao","orcid":"https://orcid.org/0000-0002-0091-2937","observed_orcids":["https://orcid.org/0000-0002-0091-2937"]},"institutions":[{"id":"https://openalex.org/I168537998","display_name":"Eli Lilly (United States)","ror":"https://ror.org/01qat3289","country_code":"US","type":"company","lineage":["https://openalex.org/I168537998"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ling Gao","raw_affiliation_strings":["9Eli Lilly and Company, Indianapolis, Indiana"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"9Eli Lilly and Company, Indianapolis, Indiana","institution_ids":["https://openalex.org/I168537998"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5038009127","display_name":"Rebecca R. Hozak","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I168537998","display_name":"Eli Lilly (United States)","ror":"https://ror.org/01qat3289","country_code":"US","type":"company","lineage":["https://openalex.org/I168537998"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Rebecca R. Hozak","raw_affiliation_strings":["9Eli Lilly and Company, Indianapolis, Indiana"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"9Eli Lilly and Company, Indianapolis, Indiana","institution_ids":["https://openalex.org/I168537998"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5028800670","display_name":"Bo H. Chao","orcid":"https://orcid.org/0000-0003-2335-5579","observed_orcids":["https://orcid.org/0000-0003-2335-5579"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Bo H. Chao","raw_affiliation_strings":["10Eli Lilly and Company, New York, New York"],"raw_orcid":"https://orcid.org/0000-0003-2335-5579","affiliations":[{"raw_affiliation_string":"10Eli Lilly and Company, New York, New York","institution_ids":[]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5028596081","display_name":"David Planchard","orcid":"https://orcid.org/0000-0002-1565-8310","observed_orcids":["https://orcid.org/0000-0002-1565-8310"]},"institutions":[{"id":"https://openalex.org/I2801843802","display_name":"Institut Gustave Roussy","ror":"https://ror.org/0321g0743","country_code":"FR","type":"facility","lineage":["https://openalex.org/I2801843802"]},{"id":"https://openalex.org/I4405269973","display_name":"Fondation Gustave Roussy","ror":"https://ror.org/05rfnt234","country_code":"FR","type":"nonprofit","lineage":["https://openalex.org/I4405269973"]}],"countries":["FR"],"is_corresponding":false,"raw_author_name":"David Planchard","raw_affiliation_strings":["11Department of Medical Oncology, Thoracic Unit, Gustave Roussy, Villejuif, France"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"11Department of Medical Oncology, Thoracic Unit, Gustave Roussy, Villejuif, France","institution_ids":["https://openalex.org/I2801843802","https://openalex.org/I4405269973"]}]}],"institutions":[],"countries_distinct_count":5,"institutions_distinct_count":15,"corresponding_author_ids":["https://openalex.org/A5014837967"],"corresponding_institution_ids":["https://openalex.org/I1334819555"],"apc_list":null,"apc_paid":null,"fwci":5.2014,"has_fulltext":false,"cited_by_count":50,"citation_normalized_percentile":{"value":0.96959728,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":89,"max":100},"biblio":{"volume":"27","issue":"4","first_page":"992","last_page":"1002"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10417","display_name":"Lung Cancer Treatments and Mutations","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10417","display_name":"Lung Cancer Treatments and Mutations","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10202","display_name":"Lung Cancer Diagnosis and Treatment","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10755","display_name":"HER2/EGFR in Cancer Research","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/ramucirumab","display_name":"ramucirumab","score":0.9819999933242798},{"id":"https://openalex.org/keywords/osimertinib","display_name":"osimertinib","score":1.0},{"id":"https://openalex.org/keywords/egfr-t790m-mutation","display_name":"T790M mutation","score":0.8539999723434448},{"id":"https://openalex.org/keywords/egfr-mutant-non-small-cell-lung-cancer","display_name":"EGFR-mutant non-small cell lung cancer","score":0.9860000014305115},{"id":"https://openalex.org/keywords/vegfr-2-inhibition","display_name":"VEGFR-2 inhibition","score":0.796999990940094},{"id":"https://openalex.org/keywords/egfr-tki-resistance","display_name":"EGFR tyrosine kinase inhibitor resistance","score":0.8930000066757202},{"id":"https://openalex.org/keywords/combination-therapy","display_name":"combination therapy","score":0.7549999952316284},{"id":"https://openalex.org/keywords/central-nervous-system-metastases","display_name":"central nervous system metastasis","score":0.8019999861717224},{"id":"https://openalex.org/keywords/circulating-tumor-dna","display_name":"circulating tumor DNA","score":0.847000002861023},{"id":"https://openalex.org/keywords/egfr-c797s-mutation","display_name":"C797S mutation","score":0.8799999952316284},{"id":"https://openalex.org/keywords/met-amplification","display_name":"MET amplification","score":0.9700000286102295},{"id":"https://openalex.org/keywords/egfr-amplification","display_name":"EGFR amplification","score":0.8339999914169312},{"id":"https://openalex.org/keywords/treatment-related-adverse-events","display_name":"treatment-related adverse events","score":0.6399999856948853}],"concepts":[{"id":"https://openalex.org/C2777626846","wikidata":"https://www.wikidata.org/wiki/Q21506464","display_name":"Osimertinib","level":5,"score":0.9667667746543884},{"id":"https://openalex.org/C2779551604","wikidata":"https://www.wikidata.org/wiki/Q7290345","display_name":"Ramucirumab","level":3,"score":0.9069300293922424},{"id":"https://openalex.org/C2777930144","wikidata":"https://www.wikidata.org/wiki/Q25100112","display_name":"T790M","level":5,"score":0.883338212966919},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.5470058917999268},{"id":"https://openalex.org/C2776256026","wikidata":"https://www.wikidata.org/wiki/Q47912","display_name":"Lung cancer","level":2,"score":0.5249980688095093},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.48152002692222595},{"id":"https://openalex.org/C143065580","wikidata":"https://www.wikidata.org/wiki/Q3285695","display_name":"Mutant","level":3,"score":0.47610458731651306},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.42323172092437744},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.40468618273735046},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.35649675130844116},{"id":"https://openalex.org/C2779438470","wikidata":"https://www.wikidata.org/wiki/Q424401","display_name":"Epidermal growth factor receptor","level":3,"score":0.29576972126960754},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.1706351935863495},{"id":"https://openalex.org/C2780580887","wikidata":"https://www.wikidata.org/wiki/Q417824","display_name":"Gefitinib","level":4,"score":0.12568894028663635},{"id":"https://openalex.org/C2778087573","wikidata":"https://www.wikidata.org/wiki/Q418369","display_name":"Erlotinib","level":4,"score":0.10139793157577515},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.0},{"id":"https://openalex.org/C104317684","wikidata":"https://www.wikidata.org/wiki/Q7187","display_name":"Gene","level":2,"score":0.0}],"mesh":[{"descriptor_ui":"D000077982","descriptor_name":"Progression-Free Survival","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000096662","descriptor_name":"Ramucirumab","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000178","descriptor_name":"Acrylamides","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D000178","descriptor_name":"Acrylamides","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D000368","descriptor_name":"Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000369","descriptor_name":"Aged, 80 and over","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000814","descriptor_name":"Aniline Compounds","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D000814","descriptor_name":"Aniline Compounds","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D000971","descriptor_name":"Antineoplastic Combined Chemotherapy Protocols","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D000971","descriptor_name":"Antineoplastic Combined Chemotherapy Protocols","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D002289","descriptor_name":"Carcinoma, Non-Small-Cell Lung","qualifier_ui":"Q000175","qualifier_name":"diagnosis","is_major_topic":false},{"descriptor_ui":"D002289","descriptor_name":"Carcinoma, Non-Small-Cell Lung","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D002289","descriptor_name":"Carcinoma, Non-Small-Cell Lung","qualifier_ui":"Q000235","qualifier_name":"genetics","is_major_topic":false},{"descriptor_ui":"D002289","descriptor_name":"Carcinoma, Non-Small-Cell Lung","qualifier_ui":"Q000401","qualifier_name":"mortality","is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007211","descriptor_name":"Indoles","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008175","descriptor_name":"Lung Neoplasms","qualifier_ui":"Q000175","qualifier_name":"diagnosis","is_major_topic":false},{"descriptor_ui":"D008175","descriptor_name":"Lung Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D008175","descriptor_name":"Lung Neoplasms","qualifier_ui":"Q000235","qualifier_name":"genetics","is_major_topic":false},{"descriptor_ui":"D008175","descriptor_name":"Lung Neoplasms","qualifier_ui":"Q000401","qualifier_name":"mortality","is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009154","descriptor_name":"Mutation","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009367","descriptor_name":"Neoplasm Staging","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D011743","descriptor_name":"Pyrimidines","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D018572","descriptor_name":"Disease-Free Survival","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D040301","descriptor_name":"Vascular Endothelial Growth Factor Receptor-2","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":false},{"descriptor_ui":"D061067","descriptor_name":"Antibodies, Monoclonal, Humanized","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D061067","descriptor_name":"Antibodies, Monoclonal, Humanized","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D066066","descriptor_name":"Response Evaluation Criteria in Solid Tumors","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D066246","descriptor_name":"ErbB Receptors","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":false},{"descriptor_ui":"D066246","descriptor_name":"ErbB Receptors","qualifier_ui":"Q000235","qualifier_name":"genetics","is_major_topic":false}],"locations_count":3,"locations":[{"id":"doi:10.1158/1078-0432.ccr-20-1690","doi":"https://doi.org/10.1158/1078-0432.ccr-20-1690","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1078-0432.ccr-20-1690","pdf_url":null,"source":{"id":"https://openalex.org/S183149254","display_name":"Clinical Cancer Research","issn_l":"1078-0432","issn":["1078-0432","1557-3265"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical Cancer Research","raw_type":"journal-article"},{"id":"pmid:33046516","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/33046516","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical cancer research : an official journal of the American Association for Cancer Research","raw_type":"Clinical Trial, Phase I"},{"id":"pmh:oai:pubmedcentral.nih.gov:8793125","doi":null,"is_oa":true,"landing_page_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/8793125","pdf_url":null,"source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"Clin Cancer Res","raw_type":"Text"}],"best_oa_location":{"id":"pmh:oai:pubmedcentral.nih.gov:8793125","doi":null,"is_oa":true,"landing_page_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/8793125","pdf_url":null,"source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"Clin Cancer Res","raw_type":"Text"},"sustainable_development_goals":[{"score":1.0,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"sustainable_development_goals_aurora":[{"score":0.8500000238418579,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[{"display_name":"Clinical Trial","id":"https://openalex.org/study-designs/clinical-trial"}],"awards":[{"id":"https://openalex.org/G9000856728","display_name":"Cancer Center Support Grant","funder_award_id":"P30CA008748","funder_id":"https://openalex.org/F4320337351","funder_display_name":"National Cancer Institute"}],"funders":[{"id":"https://openalex.org/F4320307758","display_name":"Eli Lilly and Company","ror":"https://ror.org/01qat3289"},{"id":"https://openalex.org/F4320337351","display_name":"National Cancer Institute","ror":"https://ror.org/040gcmg81"}],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":50,"referenced_works":["https://openalex.org/W1828082159","https://openalex.org/W1848068129","https://openalex.org/W1979300931","https://openalex.org/W2019607817","https://openalex.org/W2025652939","https://openalex.org/W2043166238","https://openalex.org/W2076178766","https://openalex.org/W2088540000","https://openalex.org/W2096198395","https://openalex.org/W2104759721","https://openalex.org/W2111237964","https://openalex.org/W2111662961","https://openalex.org/W2125913015","https://openalex.org/W2132157071","https://openalex.org/W2136371443","https://openalex.org/W2136601558","https://openalex.org/W2140980839","https://openalex.org/W2145835533","https://openalex.org/W2153297361","https://openalex.org/W2302258098","https://openalex.org/W2472000057","https://openalex.org/W2511999371","https://openalex.org/W2536396512","https://openalex.org/W2555516405","https://openalex.org/W2560717039","https://openalex.org/W2591655368","https://openalex.org/W2606131767","https://openalex.org/W2747965175","https://openalex.org/W2768026378","https://openalex.org/W2770828094","https://openalex.org/W2788612690","https://openalex.org/W2807660816","https://openalex.org/W2883541766","https://openalex.org/W2885289995","https://openalex.org/W2887416920","https://openalex.org/W2890374573","https://openalex.org/W2902378590","https://openalex.org/W2908573150","https://openalex.org/W2911188335","https://openalex.org/W2916137642","https://openalex.org/W2938088824","https://openalex.org/W2947845902","https://openalex.org/W2949983013","https://openalex.org/W2958083922","https://openalex.org/W2971041600","https://openalex.org/W2978677918","https://openalex.org/W2990041408","https://openalex.org/W2990950294","https://openalex.org/W3032754491","https://openalex.org/W4293241248"],"related_works":["https://openalex.org/W2890244190","https://openalex.org/W2570555860","https://openalex.org/W2768026378","https://openalex.org/W2898425871","https://openalex.org/W2888225429","https://openalex.org/W3127213275","https://openalex.org/W2981985980","https://openalex.org/W3111150650","https://openalex.org/W4403208158","https://openalex.org/W2313893717"],"abstract_inverted_index":{"Abstract":[0],"Purpose:":[1],"We":[2],"report":[3],"the":[4,12,15,23],"final":[5],"analysis":[6],"of":[7,14,166,218,236],"JVDL":[8],"(NCT02789345),":[9],"which":[10],"examined":[11],"combination":[13],"EGFR":[16,49,56,61,219,249],"tyrosine":[17],"kinase":[18],"inhibitor":[19],"(TKI)":[20],"osimertinib":[21,82,254],"plus":[22,253],"VEGFR2-directed":[24],"antibody":[25],"ramucirumab":[26,85],"in":[27,131,189,210,261],"patients":[28,47,95,154,190],"with":[29,48,68,135,191,230],"T790M-positive":[30,50,262],"EGFR-mutant":[31,263],"non\u2013small":[32],"cell":[33],"lung":[34],"cancer":[35],"(NSCLC).":[36],"Patients":[37,78,134],"and":[38,83,120,139,192,198,203,248,258],"Methods:":[39],"This":[40],"open-label,":[41],"single-arm":[42],"phase":[43],"I":[44],"study":[45],"enrolled":[46],"NSCLC,":[51],"who":[52],"had":[53,149],"progressed":[54],"following":[55],"TKI":[57],"but":[58,233],"were":[59,96,100,117],"third-generation":[60],"TKI-na\u00efve.":[62],"A":[63],"dose-limiting":[64],"toxicity":[65],"(DLT)":[66],"period":[67],"as-needed":[69],"dose":[70],"deescalation":[71],"was":[72,105,162,168,180,187],"followed":[73],"by":[74,268],"an":[75],"expansion":[76],"cohort.":[77],"received":[79],"daily":[80],"oral":[81],"intravenous":[84],"every":[86],"2":[87],"weeks":[88],"until":[89],"progression":[90],"or":[91,111,223],"discontinuation.":[92],"Results:":[93],"Twenty-five":[94],"enrolled.":[97],"No":[98],"DLTs":[99],"observed.":[101],"Median":[102,164,176],"follow-up":[103],"time":[104],"25.0":[106],"months.":[107],"Common":[108],"grade":[109,125],"3":[110],"higher":[112],"treatment-related":[113],"adverse":[114],"events":[115],"(TRAE)":[116],"hypertension":[118],"(8%)":[119],"platelet":[121],"count":[122],"decreased":[123],"(16%);":[124],"5":[126],"TRAE":[127],"(subdural":[128],"hemorrhage)":[129],"occurred":[130],"1":[132],"patient.":[133],"(N":[136,146],"=":[137,147],"10)":[138],"without":[140,193],"central":[141],"nervous":[142],"system":[143],"(CNS)":[144],"metastasis":[145,195],"15)":[148],"similar":[150],"safety":[151,257],"outcomes.":[152],"Five":[153],"remain":[155],"on":[156],"treatment.":[157],"Objective":[158],"response":[159,167],"rate":[160],"(ORR)":[161],"76%.":[163],"duration":[165],"13.4":[169],"months":[170,182],"[90%":[171],"confidence":[172],"interval":[173],"(CI):":[174],"9.6\u201321.2].":[175],"progression-free":[177],"survival":[178],"(PFS)":[179],"11.0":[181],"(90%":[183],"CI:":[184],"5.5\u201319.3).":[185],"Efficacy":[186],"observed":[188],"CNS":[194],"(ORR":[196],"60%":[197],"87%;":[199],"median":[200],"PFS":[201],"10.9":[202],"14.7":[204],"months,":[205],"respectively).":[206],"Exploratory":[207],"biomarker":[208],"analyses":[209],"circulating":[211],"tumor":[212],"DNA":[213],"suggested":[214],"that":[215],"on-treatment":[216,234],"loss":[217,235],"Exon":[220],"19":[221],"deletion":[222],"L858R":[224],"mutations,":[225],"detectable":[226],"at":[227],"baseline,":[228],"correlated":[229],"longer":[231],"PFS,":[232],"T790M":[237],"did":[238],"not.":[239],"Emergent":[240],"genetic":[241],"alterations":[242],"postprogression":[243],"included":[244],"C797S,":[245],"MET":[246],"amplification,":[247],"amplification.":[250],"Conclusions:":[251],"Ramucirumab":[252],"demonstrated":[255],"encouraging":[256],"antitumor":[259],"activity":[260],"NSCLC.":[264],"See":[265],"related":[266],"commentary":[267],"Garon,":[269],"p.":[270],"905":[271]},"counts_by_year":[{"year":2026,"cited_by_count":2},{"year":2025,"cited_by_count":3},{"year":2024,"cited_by_count":7},{"year":2023,"cited_by_count":5},{"year":2022,"cited_by_count":15},{"year":2021,"cited_by_count":17},{"year":2018,"cited_by_count":1}],"updated_date":"2026-10-31T12:09:11.096373","created_date":"2020-10-15T00:00:00"}